PHRI Senior Scientist Ashkan Shoamanesh and Scientist Aristeidis Katsanos took part in the 11th European Stroke Organization Conference (ESOC 2025), held in Helsinki, Finland.
Katsanos presented on the COVASC-ICH trial, which explores the use of colchicine for the prevention of vascular events following acute intracerebral hemorrhage.
Kudos to @ArKatsanos for his effective leadership of CoVasc-ICH! This Canada-led first RCT testing colchicine in acute ICH has provided the requisite feasibility metrics to effectively plan our global phase III trial, CoVasc-ICH 2 (https://t.co/6YsFYn90OR). Stay tuned! https://t.co/6X4B5C4B7E
— Ashkan Shoamanesh (@Ash_Shoamanesh) May 23, 2025
Shoamanesh chaired two sessions during the conference:
- CME Symposium: “Can We Find a New Way Forward in Secondary Stroke Prevention? Exploring the Rationale and Potential Roles for Factor XIa Inhibition”
- “Heart-Brain Connection: Imaging, Atrial Fibrillation and Prevention”
He also presented 2-year follow-up results from CAPTURE 2 trial: “Permanent bilateral carotid artery filters to prevent anterior circulation large vessel occlusion stroke in atrial fibrillation.”
Are permanent bilateral carotid filters useful for preventing stroke in high risk AF patients? Promising results presented by @Ash_Shoamanesh at #ESOC2025
Phase III trial is planned @ESOstroke pic.twitter.com/54JTYhCdAE— Seemant Chaturvedi (@ChaturvediNeuro) May 21, 2025
